Recruiting PHASE3 INTERVENTIONAL 1-arm NCT06747351

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Sponsor: Takeda

Conditions Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions HYQVIA SC Investigational Needle Sets TAK-881

Updated 4 times since 2025 Last updated: Jan 16, 2026 Started: May 6, 2025 Primary completion: Jun 25, 2028 Completion: Jun 25, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and is currently actively recruiting participants. Takeda leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Oct 2025 — Feb 2026 [monthly]

Recruiting PHASE3
Jul 2025 — Oct 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jan 2025 — Jul 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda
Takeda Development Center Americas, Inc.

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Athens, Greece , Barcelona, Spain , Berlin, Germany , Brescia, Italy , Buenos Aires, Argentina , Bunkyo-ku, Japan , Burlington, United States , Chapel Hill, United States , Cleveland, United States and 42 more locations